SEI Trust Company’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

SEI Trust Company’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-3,265	Closed	-$342K	–	1728
2014 Q2	$342K	Sell	3,265 -300	-8%	-$25.5K	﹤0.01%	1202
2014 Q1	$296K	Buy	+3,565	New	+$330K	﹤0.01%	1239

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

SEI Trust Company's GEVA Position: Q3 2014 in Review

SEI Trust Company sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2014, closing a stake of 3,265 shares — an estimated $342K sold.

SEI Trust Company first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $342K in Q2 2014. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

SEI Trust Company reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2014 after selling out during the quarter.
SEI Trust Company sold 3,265 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $342K.
SEI Trust Company first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
SEI Trust Company's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $342K in Q2 2014.
120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on SEI Trust Company's 13F filing for Q3 2014, filed 28 Oct 2014.